Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Procept BioRobotics (PRCT) stock in plain English

Free brief · no signupStart here
PRCTPublished Nov 8, 2026
Procept BioRobotics Corp
Healthcare · Medical Devices
Sells robotic surgery systems and single-use disposable handpieces for treating benign prostatic hyperplasia.
Assets:
San Jose headquartersHouses corporate offices and device manufacturing operations
HYDROS platformNext-generation artificial intelligence-driven robotic waterjet surgical system
Aquablation therapyPrimary surgical procedure utilizing high-velocity saline resection
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

72
OPS ScoreOperating finances
Latest quote
+2.26%$25.75
$1.48B
n/a (loss)
$351.91M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 08, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was PRCT. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Procept BioRobotics (PRCT) do?

Procept BioRobotics Corp (PRCT) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Sells robotic surgery systems and single-use disposable handpieces for treating benign prostatic hyperplasia. Combines real-time ultrasound imaging with computer-guided waterjets to resect prostate tissue autonomously. It is worth $1.48B on the market and sold $351.91M over the last year.

Market cap
$1.48B
P/E ratio
None (reported a loss)
Annual sales
$351.91M
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 08, 2026

Brands and businesses behind PRCT

  • AquaBeam Robotic System: A surgical robotic console sold to hospitals to deliver automated waterjet prostate tissue resection.
  • HYDROS Robotic System: An advanced robotic platform that uses artificial intelligence and ultrasound imaging for prostate surgery.
  • Aquablation Therapy: A minimally invasive surgical procedure that generates revenue through recurring sales of single-use handpieces.

PRCT’s flags, in plain English

Each flag is a number from Procept BioRobotics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 08, 2026.

Stupid Cash

Can pay this year's bills 5.9 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Still Climbing

Sales up 109% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Low debt

Low debt, only 23% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Burning Cash

Losing money, profit margin of -32.6%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

1 more green flag and 2 more risk notes open with the free trial. Try it free for 7 days.

Questions about PRCT

How big is Procept BioRobotics?

Procept BioRobotics’ market cap is $1.48B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $351.91M: what customers paid the company over the last year, before any costs.

What is PRCT’s P/E ratio?

PRCT has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with PRCT?

The business remains unprofitable and depends heavily on commercial adoption of a single procedure type. That is one risk on Procept BioRobotics’ card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Procept BioRobotics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. PRCT’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card